Titre : Ouganda

Ouganda : Questions médicales fréquentes

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer le paludisme en Ouganda ?

Le diagnostic se fait par des tests sanguins, comme le frottis ou le test rapide.
Paludisme Diagnostic médical
#2

Quels tests pour la tuberculose en Ouganda ?

La tuberculose est diagnostiquée par des tests cutanés, des radiographies et des cultures.
Tuberculose Tests diagnostiques
#3

Comment identifier le VIH en Ouganda ?

Le VIH est détecté par des tests sanguins, notamment les tests ELISA et PCR.
VIH Diagnostic du VIH
#4

Quels examens pour les maladies tropicales ?

Des analyses sanguines et des examens cliniques sont utilisés pour diagnostiquer ces maladies.
Maladies tropicales Diagnostic médical
#5

Comment diagnostiquer la fièvre jaune ?

Le diagnostic repose sur des tests sérologiques et l'historique de vaccination.
Fièvre jaune Diagnostic médical

Symptômes 5

#1

Quels sont les symptômes du paludisme ?

Fièvre, frissons, sueurs, maux de tête et douleurs musculaires sont fréquents.
Paludisme Symptômes
#2

Quels signes de tuberculose ?

Toux persistante, perte de poids, sueurs nocturnes et fatigue sont des indicateurs.
Tuberculose Symptômes
#3

Quels symptômes du VIH ?

Les symptômes initiaux incluent fièvre, fatigue, et ganglions lymphatiques enflés.
VIH Symptômes
#4

Quels signes de choléra ?

Diarrhée aqueuse sévère, vomissements et déshydratation rapide sont typiques.
Choléra Symptômes
#5

Quels symptômes de la fièvre jaune ?

Fièvre, douleurs musculaires, et jaunisse sont des symptômes clés de la maladie.
Fièvre jaune Symptômes

Prévention 5

#1

Comment prévenir le paludisme ?

Utiliser des moustiquaires, des insecticides et prendre des médicaments préventifs.
Paludisme Prévention
#2

Quelles mesures pour prévenir la tuberculose ?

Vaccination BCG et dépistage régulier des personnes à risque sont recommandés.
Tuberculose Prévention
#3

Comment prévenir le VIH ?

Utiliser des préservatifs et se faire dépister régulièrement sont des mesures clés.
VIH Prévention
#4

Quelles précautions contre le choléra ?

Boire de l'eau potable, se laver les mains et éviter les aliments crus sont essentiels.
Choléra Prévention
#5

Comment prévenir la fièvre jaune ?

La vaccination est la méthode la plus efficace pour prévenir la fièvre jaune.
Fièvre jaune Vaccination

Traitements 5

#1

Quel traitement pour le paludisme ?

Les antipaludiques comme l'artémisinine sont utilisés pour traiter le paludisme.
Paludisme Traitement
#2

Comment traiter la tuberculose ?

Le traitement standard inclut une combinaison d'antibiotiques sur plusieurs mois.
Tuberculose Traitement
#3

Quel traitement pour le VIH ?

Les thérapies antirétrovirales (TAR) sont essentielles pour gérer le VIH.
VIH Traitement antirétroviral
#4

Comment traiter le choléra ?

La réhydratation orale et les antibiotiques sont cruciaux pour traiter le choléra.
Choléra Traitement
#5

Quel traitement pour la fièvre jaune ?

Il n'existe pas de traitement spécifique, la vaccination est la meilleure prévention.
Fièvre jaune Prévention

Complications 5

#1

Quelles complications du paludisme ?

Les complications incluent l'anémie, le coma et la défaillance organique.
Paludisme Complications
#2

Quelles complications de la tuberculose ?

La tuberculose peut entraîner des lésions pulmonaires et une dissémination systémique.
Tuberculose Complications
#3

Quelles complications du VIH ?

Le VIH peut mener à des infections opportunistes et à des cancers associés.
VIH Complications
#4

Quelles complications du choléra ?

La déshydratation sévère peut entraîner un choc hypovolémique et la mort.
Choléra Complications
#5

Quelles complications de la fièvre jaune ?

Les complications incluent des lésions hépatiques et des troubles de la coagulation.
Fièvre jaune Complications

Facteurs de risque 5

#1

Quels sont les facteurs de risque du paludisme ?

Vivre dans des zones endémiques, absence de moustiquaires et immunité faible.
Paludisme Facteurs de risque
#2

Quels facteurs de risque pour la tuberculose ?

Conditions de vie surpeuplées, immunodépression et contact avec des malades.
Tuberculose Facteurs de risque
#3

Quels facteurs de risque pour le VIH ?

Relations sexuelles non protégées, partage de seringues et absence de dépistage.
VIH Facteurs de risque
#4

Quels facteurs de risque pour le choléra ?

Accès limité à l'eau potable et à l'assainissement, ainsi que la consommation d'aliments contaminés.
Choléra Facteurs de risque
#5

Quels facteurs de risque pour la fièvre jaune ?

Voyages dans des zones endémiques sans vaccination et exposition aux moustiques.
Fièvre jaune Facteurs de risque
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Ouganda : Questions médicales les plus fréquentes", "headline": "Ouganda : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Ouganda : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-20", "dateModified": "2026-06-10", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Ouganda" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Afrique de l'Est", "url": "https://questionsmedicales.fr/mesh/D000351", "about": { "@type": "MedicalCondition", "name": "Afrique de l'Est", "code": { "@type": "MedicalCode", "code": "D000351", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.058.290.120" } } }, "about": { "@type": "MedicalCondition", "name": "Ouganda", "alternateName": "Uganda", "code": { "@type": "MedicalCode", "code": "D014454", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jackson Orem", "url": "https://questionsmedicales.fr/author/Jackson%20Orem", "affiliation": { "@type": "Organization", "name": "Uganda Cancer Institute, Upper Mulago Hill Rd, Kampala, Uganda." } }, { "@type": "Person", "name": "Henry Ddungu", "url": "https://questionsmedicales.fr/author/Henry%20Ddungu", "affiliation": { "@type": "Organization", "name": "Uganda Cancer Institute, Upper Mulago Hill Rd, Kampala, Uganda." } }, { "@type": "Person", "name": "Moses R Kamya", "url": "https://questionsmedicales.fr/author/Moses%20R%20Kamya", "affiliation": { "@type": "Organization", "name": "Makerere University College of Health Sciences." } }, { "@type": "Person", "name": "Nelson K Sewankambo", "url": "https://questionsmedicales.fr/author/Nelson%20K%20Sewankambo", "affiliation": { "@type": "Organization", "name": "College of Health Sciences, School of Medicine, Department of Medicine, Makerere University, Kampala, Uganda." } }, { "@type": "Person", "name": "Adrian Kayanja", "url": "https://questionsmedicales.fr/author/Adrian%20Kayanja", "affiliation": { "@type": "Organization", "name": "Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda. Electronic address: adriankayanja@gmail.com." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Exploration of clinical ethics consultation in Uganda: a case study of Uganda Cancer Institute.", "datePublished": "2024-08-09", "url": "https://questionsmedicales.fr/article/39123154", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12910-024-01085-1" } }, { "@type": "ScholarlyArticle", "name": "The Uganda housing modification study - association between housing characteristics and malaria burden in a moderate to high transmission setting in Uganda.", "datePublished": "2024-07-30", "url": "https://questionsmedicales.fr/article/39080697", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12936-024-05051-5" } }, { "@type": "ScholarlyArticle", "name": "The epidemiology of antibiotic-resistant clinical pathogens in Uganda.", "datePublished": "2024-08-30", "url": "https://questionsmedicales.fr/article/39212655", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.7189/jogh.14.04184" } }, { "@type": "ScholarlyArticle", "name": "Clinical officers in Uganda: Training and workforce role.", "datePublished": "2024-06-25", "url": "https://questionsmedicales.fr/article/38916374", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/01.JAA.0000000000000027" } }, { "@type": "ScholarlyArticle", "name": "Policy analysis of the Global Financing Facility in Uganda.", "datePublished": "2024-06-19", "url": "https://questionsmedicales.fr/article/38979635", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/16549716.2024.2336310" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Régions géographiques", "item": "https://questionsmedicales.fr/mesh/D005842" }, { "@type": "ListItem", "position": 3, "name": "Afrique", "item": "https://questionsmedicales.fr/mesh/D000349" }, { "@type": "ListItem", "position": 4, "name": "Afrique subsaharienne", "item": "https://questionsmedicales.fr/mesh/D017954" }, { "@type": "ListItem", "position": 5, "name": "Afrique de l'Est", "item": "https://questionsmedicales.fr/mesh/D000351" }, { "@type": "ListItem", "position": 6, "name": "Ouganda", "item": "https://questionsmedicales.fr/mesh/D014454" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Ouganda - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Ouganda", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2026-08-26", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Ouganda", "description": "Comment diagnostiquer le paludisme en Ouganda ?\nQuels tests pour la tuberculose en Ouganda ?\nComment identifier le VIH en Ouganda ?\nQuels examens pour les maladies tropicales ?\nComment diagnostiquer la fièvre jaune ?", "url": "https://questionsmedicales.fr/mesh/D014454#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Ouganda", "description": "Quels sont les symptômes du paludisme ?\nQuels signes de tuberculose ?\nQuels symptômes du VIH ?\nQuels signes de choléra ?\nQuels symptômes de la fièvre jaune ?", "url": "https://questionsmedicales.fr/mesh/D014454#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Ouganda", "description": "Comment prévenir le paludisme ?\nQuelles mesures pour prévenir la tuberculose ?\nComment prévenir le VIH ?\nQuelles précautions contre le choléra ?\nComment prévenir la fièvre jaune ?", "url": "https://questionsmedicales.fr/mesh/D014454#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Ouganda", "description": "Quel traitement pour le paludisme ?\nComment traiter la tuberculose ?\nQuel traitement pour le VIH ?\nComment traiter le choléra ?\nQuel traitement pour la fièvre jaune ?", "url": "https://questionsmedicales.fr/mesh/D014454#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Ouganda", "description": "Quelles complications du paludisme ?\nQuelles complications de la tuberculose ?\nQuelles complications du VIH ?\nQuelles complications du choléra ?\nQuelles complications de la fièvre jaune ?", "url": "https://questionsmedicales.fr/mesh/D014454#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Ouganda", "description": "Quels sont les facteurs de risque du paludisme ?\nQuels facteurs de risque pour la tuberculose ?\nQuels facteurs de risque pour le VIH ?\nQuels facteurs de risque pour le choléra ?\nQuels facteurs de risque pour la fièvre jaune ?", "url": "https://questionsmedicales.fr/mesh/D014454#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer le paludisme en Ouganda ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par des tests sanguins, comme le frottis ou le test rapide." } }, { "@type": "Question", "name": "Quels tests pour la tuberculose en Ouganda ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "La tuberculose est diagnostiquée par des tests cutanés, des radiographies et des cultures." } }, { "@type": "Question", "name": "Comment identifier le VIH en Ouganda ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Le VIH est détecté par des tests sanguins, notamment les tests ELISA et PCR." } }, { "@type": "Question", "name": "Quels examens pour les maladies tropicales ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des analyses sanguines et des examens cliniques sont utilisés pour diagnostiquer ces maladies." } }, { "@type": "Question", "name": "Comment diagnostiquer la fièvre jaune ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests sérologiques et l'historique de vaccination." } }, { "@type": "Question", "name": "Quels sont les symptômes du paludisme ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, frissons, sueurs, maux de tête et douleurs musculaires sont fréquents." } }, { "@type": "Question", "name": "Quels signes de tuberculose ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Toux persistante, perte de poids, sueurs nocturnes et fatigue sont des indicateurs." } }, { "@type": "Question", "name": "Quels symptômes du VIH ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes initiaux incluent fièvre, fatigue, et ganglions lymphatiques enflés." } }, { "@type": "Question", "name": "Quels signes de choléra ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Diarrhée aqueuse sévère, vomissements et déshydratation rapide sont typiques." } }, { "@type": "Question", "name": "Quels symptômes de la fièvre jaune ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, douleurs musculaires, et jaunisse sont des symptômes clés de la maladie." } }, { "@type": "Question", "name": "Comment prévenir le paludisme ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des moustiquaires, des insecticides et prendre des médicaments préventifs." } }, { "@type": "Question", "name": "Quelles mesures pour prévenir la tuberculose ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Vaccination BCG et dépistage régulier des personnes à risque sont recommandés." } }, { "@type": "Question", "name": "Comment prévenir le VIH ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des préservatifs et se faire dépister régulièrement sont des mesures clés." } }, { "@type": "Question", "name": "Quelles précautions contre le choléra ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Boire de l'eau potable, se laver les mains et éviter les aliments crus sont essentiels." } }, { "@type": "Question", "name": "Comment prévenir la fièvre jaune ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "La vaccination est la méthode la plus efficace pour prévenir la fièvre jaune." } }, { "@type": "Question", "name": "Quel traitement pour le paludisme ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les antipaludiques comme l'artémisinine sont utilisés pour traiter le paludisme." } }, { "@type": "Question", "name": "Comment traiter la tuberculose ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement standard inclut une combinaison d'antibiotiques sur plusieurs mois." } }, { "@type": "Question", "name": "Quel traitement pour le VIH ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les thérapies antirétrovirales (TAR) sont essentielles pour gérer le VIH." } }, { "@type": "Question", "name": "Comment traiter le choléra ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La réhydratation orale et les antibiotiques sont cruciaux pour traiter le choléra." } }, { "@type": "Question", "name": "Quel traitement pour la fièvre jaune ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de traitement spécifique, la vaccination est la meilleure prévention." } }, { "@type": "Question", "name": "Quelles complications du paludisme ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'anémie, le coma et la défaillance organique." } }, { "@type": "Question", "name": "Quelles complications de la tuberculose ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "La tuberculose peut entraîner des lésions pulmonaires et une dissémination systémique." } }, { "@type": "Question", "name": "Quelles complications du VIH ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Le VIH peut mener à des infections opportunistes et à des cancers associés." } }, { "@type": "Question", "name": "Quelles complications du choléra ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La déshydratation sévère peut entraîner un choc hypovolémique et la mort." } }, { "@type": "Question", "name": "Quelles complications de la fièvre jaune ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des lésions hépatiques et des troubles de la coagulation." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque du paludisme ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Vivre dans des zones endémiques, absence de moustiquaires et immunité faible." } }, { "@type": "Question", "name": "Quels facteurs de risque pour la tuberculose ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Conditions de vie surpeuplées, immunodépression et contact avec des malades." } }, { "@type": "Question", "name": "Quels facteurs de risque pour le VIH ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Relations sexuelles non protégées, partage de seringues et absence de dépistage." } }, { "@type": "Question", "name": "Quels facteurs de risque pour le choléra ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Accès limité à l'eau potable et à l'assainissement, ainsi que la consommation d'aliments contaminés." } }, { "@type": "Question", "name": "Quels facteurs de risque pour la fièvre jaune ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Voyages dans des zones endémiques sans vaccination et exposition aux moustiques." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 10/06/2026

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Henry Ddungu

4 publications dans cette catégorie

Affiliations :
  • Uganda Cancer Institute, Upper Mulago Hill Rd, Kampala, Uganda.
  • Palliative Care Association of Uganda, Block 383, Plot 8804, Kitende, Entebbe Road, Uganda.

Moses R Kamya

4 publications dans cette catégorie

Affiliations :
  • Makerere University College of Health Sciences.
  • Infectious Diseases Research Collaboration, 2C Nakasero Hill Road, Kampala, Uganda.

Nelson K Sewankambo

3 publications dans cette catégorie

Affiliations :
  • College of Health Sciences, School of Medicine, Department of Medicine, Makerere University, Kampala, Uganda.

Adrian Kayanja

3 publications dans cette catégorie

Affiliations :
  • Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda. Electronic address: adriankayanja@gmail.com.
Publications dans "Ouganda" :

Julia Downing

3 publications dans cette catégorie

Affiliations :
  • International Children's Palliative Care Network, Suite 1b, Whitefrairs, Lewins Mead, Bristol BS1 2NT, UK.
  • Palliative care Education and Research Consortium, PO Box 6245, Kyadondo Block 262, Plot 9, Kibuye, Makindye, Kampala, Uganda.
  • Makerere University, University Rd, Kampala, Uganda.

Samuel Gonahasa

3 publications dans cette catégorie

Affiliations :
  • Infectious Diseases Research Collaboration, 2C Nakasero Hill Road, Kampala, Uganda.

Agaba Katureebe

3 publications dans cette catégorie

Affiliations :
  • Infectious Diseases Research Collaboration, 2C Nakasero Hill Road, Kampala, Uganda.

Christine Muhumuza

3 publications dans cette catégorie

Affiliations :
  • Duke Division of Global Neurosurgery and Neurology, Department of Neurosurgery, Box 3807 Duke University Medical Center, Durham, NC 27705, USA; Makerere University School of Public Health, Department of Epidemiology and Biostatistics, New Mulago complex, P.O. Box 7072, Kampala, Uganda.

Anthony T Fuller

3 publications dans cette catégorie

Affiliations :
  • Duke Division of Global Neurosurgery and Neurology, Department of Neurosurgery, Box 3807 Duke University Medical Center, Durham, NC 27705, USA; Duke Global Health Institute, 310 Trent Dr, Durham, NC 27710, USA; Duke University, School of Medicine, 3100 Tower Blvd, Durham, NC 27707, USA.

Michael M Haglund

3 publications dans cette catégorie

Affiliations :
  • Duke Division of Global Neurosurgery and Neurology, Department of Neurosurgery, Box 3807 Duke University Medical Center, Durham, NC 27705, USA; Duke Global Health Institute, 310 Trent Dr, Durham, NC 27710, USA; Duke University, School of Medicine, 3100 Tower Blvd, Durham, NC 27707, USA.

Mayi Mayega Nanyonga

2 publications dans cette catégorie

Affiliations :
  • College of Health Sciences, School of Medicine, Department of Anatomy, Makerere University, Kampala, Uganda. maimayega@gmail.com.
  • Joint Clinical Research Center, Lubowa, Kampala, Uganda. maimayega@gmail.com.

Paul Kutyabami

2 publications dans cette catégorie

Affiliations :
  • College of Health Sciences, School of Health Sciences, Department of Pharmacy, Makerere University, Kampala, Uganda.

Olivia Kituuka

2 publications dans cette catégorie

Affiliations :
  • College of Health Sciences, School of Medicine, Department of Surgery, Makerere University, Kampala, Uganda.

Olivia Nankinga

2 publications dans cette catégorie

Affiliations :
  • Department of Population Studies, School of Statistics and Planning, College of Business and Management Sciences, Makerere University, Kampala, Uganda. onankinga@gmail.com.

Sam Olum

2 publications dans cette catégorie

Affiliations :
  • Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda; Department of Medicine, Gulu University, Lacor, Uganda. Electronic address: soketokeny@gmail.com.
Publications dans "Ouganda" :

Anthony Muyingo

2 publications dans cette catégorie

Affiliations :
  • Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda. Electronic address: muyingomd@gmail.com.
Publications dans "Ouganda" :

Sources (1174 au total)

Exploration of clinical ethics consultation in Uganda: a case study of Uganda Cancer Institute.

Globally, healthcare providers (HCPs), hospital administrators, patients and their caretakers are increasingly confronted with complex moral, social, cultural, ethical, and legal dilemmas during clini... This phenomenological qualitative study utilized in-depth interviews (IDIs) and focus group discussions (FGDs) to collect data from Uganda Cancer Institute (UCI) staff, patients, and caretakers who we... The study revealed there was no formal committee or mechanism dedicated to resolving ethical dilemmas at the UCI. Instead, ethical dilemmas were addressed in six forums: individual consultations, tumo... The fora employed at the UCI to address ethical dilemmas were implicit, involving decisions made through various structures without the guidance of personnel well-versed in medical or clinical ethics....

The Uganda housing modification study - association between housing characteristics and malaria burden in a moderate to high transmission setting in Uganda.

Scale up of proven malaria control interventions has not been sufficient to control malaria in Uganda, emphasizing the need to explore innovative new approaches. Improved housing is one such promising... Between October and November 2021, a household survey was conducted in 1500 randomly selected households in Jinja and Luuka districts. Information on demographics, housing characteristics, use of mala... Most (65.5%) of the households surveyed lived in traditional houses. Most of the houses had closed eaves (85.5%), however, the use of other protective features like window/vent screens and installed c... The study found that even after adjusting for wealth, higher quality housing had a moderate protective effect against malaria, on top of the protection already afforded by recently distributed nets....

The epidemiology of antibiotic-resistant clinical pathogens in Uganda.

Antibiotic resistance (ABR) is a global challenge, and its control depends on robust evidence primarily derived from surveillance systems.... We utilised a national surveillance data set to demonstrate how such evidence can be systematically generated. In doing so, we characterised the ABR profiles of priority clinical pathogens, identified... Of the 12 262 samples collected between 2019-21, we analysed 9033 with complete metadata. ABR was steadily increasing at a rate of 0.5% per year, with a surge in 2021 and the highest and lowest levels... ABR is indeed a silent pandemic, and our results suggest it is increasing at 0.5% per year, with a notable surge in 2021 likely due to coronavirus disease 2019 (COVID-19). Of concern, ABR and MDR are ...

Policy analysis of the Global Financing Facility in Uganda.

In 2015, Uganda joined the Global Financing Facility (GFF), a Global Health Initiative for Reproductive, Maternal, Newborn, Child, and Adolescent Health (RMNCAH). Similar initiatives have been found t... To understand the policy process and contextual factors in Uganda that influenced the content of the GFF policy documents (Investment Case and Project Appraisal).... We conducted a qualitative policy analysis. The data collection included a document review of national RMNCAH policy documents and key informant interviews with national stakeholders involved in the d... The process of developing the GFF documents unfolded rapidly with a strong country-led approach by the government. Work commenced in late 2015; the Investment Case was published in April 2016 and the ... The learnings from this study provide insights into the translation of globally conceived health initiatives at country level, highlighting enablers and challenges. The study shows the challenges of t...

Community tuberculosis screening, testing and care, Uganda.

To assess the effectiveness of a community-based tuberculosis and leprosy intervention in which village health teams and health workers conduct door-to-door tuberculosis screening, targeted screenings... We conducted a before-and-after implementation study in Uganda to assess the effectiveness of the community tuberculosis intervention by looking at reach, outputs, adoption and effectiveness of the in... Over 5 days, campaign 1 screened 1 289 213 people (2.9% of the general population), of whom 179 144 (13.9%) fulfilled the presumptive tuberculosis criteria, and 4043 (2.3%) were diagnosed with bacteri... This community tuberculosis screening initiative is effective. However, continuous monitoring and adaptations are needed to overcome context-specific implementation challenges....

Costs and resource distribution of direct services for HIV in Uganda.

In high HIV-burden countries like Uganda, financing and resource allocation for HIV services have rapidly evolved. This study aimed to employ time-driven activity-based costing (TDABC) to examine the ... A cross-sectional study.... This study was conducted at 31 health facilities throughout Uganda: 16 level III health centres, 10 level IV health centres and 5 district hospitals.... 1119 persons receiving HIV services in 2020.... We conducted TDABC to quantify costs, resource consumption and duration of service provision associated with antiretroviral therapy, prevention of mother-to-child transmission, HIV counselling and tes... The mean cost of services ranged from US$8.18 per visit for HCT to US$32.28 for VMMC. In terms of disparities, those in the Western region received more provider time during visits compared with other... Costs and resources for HIV care vary widely throughout Uganda. This variation requires careful consideration: some sources of variation may be indicative of vertical and horizontal equity within the ...

Pilot bowel management program at Mbarara Hospital, Uganda.

Children with Hirschsprung's disease (HD) and anorectal malformations (ARM) may benefit from a bowel management program (BMP) to treat constipation and fecal incontinence. This study describes a pilot... Patients treated for HD or ARM were recruited for the BMP. Local staff underwent training and progressively took over decision-making. The rates of patient involuntary bowel movements (IBMs) and provi... Ten staff-2 surgeons, 6 nurses and 2 physiotherapists-and 12 patients participated. Patient median age was 4.5 years (IQR 3-6.6) and ten were male. Ten reported at least daily IBMs prior to the BMP. A... We describe the first BMP in Uganda. BMPs can successfully treat constipation and fecal incontinence in low-income countries, although there are challenges with resources and follow-up....

Sudan virus disease super-spreading, Uganda, 2022.

On 20 September 2022, Uganda declared its fifth Sudan virus disease (SVD) outbreak, culminating in 142 confirmed and 22 probable cases. The reproductive rate (R) of this outbreak was 1.25. We describe... In this descriptive cross-sectional study, we defined a super-spreader person (SSP) as any person with real-time polymerase chain reaction (RT-PCR) confirmed SVD linked to the infection of ≥ 13 other ... Two SSPs (Patient A, a 33-year-old male, and Patient B, a 26-year-old male) were identified, and linked to the infection of one probable and 50 confirmed secondary cases. Both SSPs lived in the same p... Extended time in the community while ill, social interactions, cross-district travel for treatment, and religious practices contributed to SVD super-spreading. Intensive community engagement and aware...

Trusted sources of information on COVID-19 vaccine in Uganda.

The COVID-19 pandemic has dramatically impacted communities worldwide, particularly in developing countries. To successfully control the pandemic, correct information and more than 80% vaccine coverag... We conducted a cross-sectional study on 587 adult population members in northern Uganda. Single-stage stratified and systematic sampling methods were used to select participants from northern Uganda. ... In a study of 587 participants, most were males, 335(57.1%), in the age group of 25-34 years, 180(31.4%), and the most trusted source of COVID-19 vaccine information were the traditional media sources... The most trusted sources of COVID-19 vaccine information in northern Uganda were Televisions, Radios, and Newspapers. The trusted sources of COVID-19 vaccine information were not significantly differe...